Hypertension complicated by heart failure and stroke: symptom recognition and blood pressure management
Hypertension complicated by heart failure: Hypertension is a common cause of heart failure, and it is more likely to occur when accompanied by myocardial ischemia, especially in elderly patients with hypertension, where the risk of heart failure is even greater. In cases of severe hypertension and malignant hypertension, if blood pressure remains high, or if accompanied by myocardial ischemia or even myocardial infarction, acute left ventricular failure can occur, manifesting as acute pulmonary edema, sudden orthopnea, dyspnea, coughing up pink frothy sputum, central cyanosis (cyanosis, also known as bluish-purple discoloration of the skin and mucous membranes, is most easily seen in peripheral circulatory areas with thinner skin, less pigment, and richer capillary networks, such as the lips, tip of the nose, cheeks, auricles, and gums), oliguria, and decreased blood pressure. In severe cases, cardiogenic shock may occur. On the other hand, chronic left ventricular dysfunction caused by hypertension can also lead to long-term pulmonary hypertension, which can eventually result in congestive heart failure. Antihypertensive treatment can reduce the probability of heart failure by at least 50%. Especially for the elderly, actively controlling blood pressure can significantly reduce the incidence of heart failure.
Pulmonary hypertension is a pathological state where pulmonary circulation pressure is higher than normal. It often occurs as a complication of cardiopulmonary diseases, but can also be caused by pulmonary vascular disease itself. Pulmonary hypertension can lead to right ventricular hypertrophy or cor pulmonale. Clinical manifestations include fatigue, exertional dyspnea, syncope, and hemoptysis; increased jugular venous pulsation; electrocardiogram showing right axis deviation, pulmonary P waves, right ventricular hypertrophy, and right bundle branch block; chest X-ray showing pulmonary artery segment protrusion and widening of the right lower pulmonary artery; and echocardiography showing right atrial and right ventricular enlargement and signs of pulmonary hypertension.
Hypertension complicated by cerebrovascular accidents: Cerebrovascular accidents, also known as "stroke" or "cerebral apoplexy," are caused by hypertension, a major risk factor. Hypertension can lead to both hemorrhagic stroke and cerebral infarction. The clinical manifestations of cerebral hemorrhage are related to the location and amount of bleeding. The onset of stroke is often sudden, with severe cases presenting with hemiplegia leading to falls, rapid onset of coma, deep breathing with snoring, slowed or increased heart rate, vomiting, incontinence, and loss of physiological reflexes. Cerebral thrombosis, on the other hand, has a slow onset, often occurring during rest or sleep. Symptoms typically begin with dizziness, limb numbness, and aphasia, followed by gradual hemiplegia, generally without coma or only with brief periods of unconsciousness.
Numerous clinical studies have confirmed that effective blood pressure control in hypertensive patients can significantly reduce the incidence of stroke (especially hemorrhagic stroke) caused by hypertension. Approximately 70% of cerebrovascular accident patients often experience the following warning signs before the onset of the stroke:
(1) Transient ischemic attack (TIA): characterized by brief loss of consciousness, speech disturbances, dizziness or nausea and vomiting, sudden falls or simple diplopia, blindness, and incontinence. These symptoms can last for varying durations, from seconds to minutes to hours, but never more than 24 hours. Symptoms usually disappear completely within 24 hours without leaving any sequelae. If left untreated, transient ischemic attacks (TIAs) can recur, with the highest recurrence rate within a few weeks. Approximately one-third of these cases develop into a full-blown stroke. Currently, it is believed that most TIAs are not transient ischemic attacks, but rather small vessel lacunar infarctions.
(2) Large fluctuations in blood pressure: Significant fluctuations in blood pressure, either high or low, even with a constant dose of antihypertensive medication or without any specific triggers, often become triggers for hemorrhagic stroke.
(3) Motor and sensory abnormalities: Such as clumsy limb movements, unsteady grip, asymmetrical mouth, tongue deviation to one side, unsteady gait, skewed walking direction, numbness in the limbs, especially unilateral, or accompanied by numbness in the mouth and face.
(4) Abnormal mental state: Abnormal personality traits, such as taciturnity and isolation, or excessive talking and irritability; some may exhibit lethargy and apathy.
(5) Existing symptoms worsen: Symptoms such as headache, head distension, palpitations, chest tightness, irritability, and insomnia that are usually present become significantly worse.
How to select lipid-lowering drugs and combination therapy strategies for dyslipidemia
Statins are the first-line lipid-lowering drugs, with the core objective of lowering LDL-C in the blood. For mixed hyperlipidemia, single-drug therapy or combination therapy with ezetimibe, fibrates, etc., should be selected according to the blood lipid levels. When using combination therapy, the risks of liver enzyme and muscle damage should be carefully considered to ensure the safety of lipid-lowering treatment.
2026-03-14Treatment goals and medication strategies for dyslipidemia in diabetic patients
Dyslipidemia in diabetic patients is characterized by high triglycerides (TG) and low HDL-C, but the primary goal of lipid-lowering therapy remains reducing LDL-C. Individuals over 40 years of age should aim to control their LDL-C below 2.6 mmol/L, and those with cardiovascular disease require even stricter lipid management.
2026-03-14Treatment goals and key points of lipid regulation for dyslipidemia in special populations
Patients with metabolic syndrome, stroke, and chronic kidney disease are all at high risk for dyslipidemia. Lipid-lowering therapy aims to reduce LDL-C, with some patients requiring intensive treatment to below 1.8 mmol/L. Patients with chronic kidney disease should be aware of the risk of statin myopathy and may need to combine ezetimibe with statins if necessary.
2026-03-14